Brief: Adagene Announces FDA Clearance Of Ind For Phase 1B/2 Trial Of Anti-CTLA-4 Monoclonal Antibody Adg116
29/11/2021 21:07
Nov 29 (Reuters) - Adagene Inc 978y.F :
* ADAGENE ANNOUNCES FDA CLEARANCE OF IND FOR PHASE 1B/2
TRIAL OF
ANTI-CTLA-4 MONOCLONAL ANTIBODY ADG116 IN COMBINATION THERAPY
WITH ANTI-PD-1 ANTIBODY PEMBROLIZUMAB
Source text for Eikon: ID:nGNX8KB301
Further company coverage: 978y.F
Recent news on Adagene
See all newsBrief: Adagene To Begin Phase 1 Study Of ADG138 For Advanced Solid Tumors In Q4 2026
Brief: Adagene Announces That Third Arc Bio Has Selected First Lead Candidate Under Amended Strategic Collaboration For Development Of Masked Cd3 T Cell Engagers Utilizing Safebody® Technology
Brief: Adagene Inc Announces Offering Of American Depositary Shares
Brief: Adagene Announces FDA Fast Track Designation For Muzastotug (Adg126)
Brief: Adagene Expands SAFEBody Deal With Exelixis To Develop Third Novel Masked Antibody-Drug Conjugate